Source:http://linkedlifedata.com/resource/pubmed/id/15919446
Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions |
umls-concept:C0001563,
umls-concept:C0021853,
umls-concept:C0023911,
umls-concept:C0085149,
umls-concept:C0178602,
umls-concept:C0205265,
umls-concept:C0376209,
umls-concept:C0376387,
umls-concept:C0376622,
umls-concept:C0441889,
umls-concept:C0456081,
umls-concept:C1555582,
umls-concept:C1704939,
umls-concept:C1823242
|
pubmed:issue |
4
|
pubmed:dateCreated |
2005-5-27
|
pubmed:abstractText |
The role of intestinal P-glycoprotein (encoded by the MDR1/ABCB1 gene) and/or metabolic enzyme CYP3A4 for tacrolimus therapy was examined in recipients of living-donor liver transplantation (LDLT), under the hypothesis that these proteins are factors for pharmacokinetic variability. The intestinal mRNA expression level of MDR1 and CYP3A4 was evaluated by real-time polymerase chain reaction (PCR), using the upper jejunum from a part of the Roux-en-Y limb for biliary reconstruction at LDLT. For 7 days postoperatively, good inverse correlation was found between the tacrolimus concentration/dose (C/D) ratio and the intestinal mRNA level of MDR1 (r = -0.776), but not of CYP3A4 (r = -0.096), in the 46 cases. After classifying the patients according to median of the intestinal MDR1 mRNA expression, the oral dose of tacrolimus in the high-MDR1 group was approximately twofold higher than in the low-MDR1 group (P < .001), whereas its trough level was similar between the two groups. In addition, the correlation between the intestinal MDR1 mRNA level and the tacrolimus C/D ratio was confirmed with a larger population (r = -0.645, n = 104). Using the regression line between the intestinal MDR1 mRNA level and tacrolimus C/D ratio, we could prospectively predict the individual C/D ratio of tacrolimus immediately after LDLT. Known genetic variations of the MDR1 gene had no effect on intestinal MDR1 mRNA level and tacrolimus C/D ratio in LDLT patients. This suggests that the intestinal mRNA level of MDR1 is a useful molecular marker for determination of the personalized oral dose of tacrolimus in recipients of LDLT immediately after surgery.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/CYP3A protein, human,
http://linkedlifedata.com/resource/pubmed/chemical/CYP3A4 protein, human,
http://linkedlifedata.com/resource/pubmed/chemical/Cytochrome P-450 CYP3A,
http://linkedlifedata.com/resource/pubmed/chemical/Cytochrome P-450 Enzyme System,
http://linkedlifedata.com/resource/pubmed/chemical/Genetic Markers,
http://linkedlifedata.com/resource/pubmed/chemical/Immunosuppressive Agents,
http://linkedlifedata.com/resource/pubmed/chemical/P-Glycoprotein,
http://linkedlifedata.com/resource/pubmed/chemical/RNA, Messenger,
http://linkedlifedata.com/resource/pubmed/chemical/Tacrolimus
|
pubmed:status |
MEDLINE
|
pubmed:month |
May
|
pubmed:issn |
0041-1345
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
37
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
1728-9
|
pubmed:dateRevised |
2008-11-21
|
pubmed:meshHeading |
pubmed-meshheading:15919446-Administration, Oral,
pubmed-meshheading:15919446-Cytochrome P-450 CYP3A,
pubmed-meshheading:15919446-Cytochrome P-450 Enzyme System,
pubmed-meshheading:15919446-Gene Expression Regulation,
pubmed-meshheading:15919446-Genetic Markers,
pubmed-meshheading:15919446-Humans,
pubmed-meshheading:15919446-Immunosuppressive Agents,
pubmed-meshheading:15919446-Intestinal Mucosa,
pubmed-meshheading:15919446-Liver Transplantation,
pubmed-meshheading:15919446-Living Donors,
pubmed-meshheading:15919446-P-Glycoprotein,
pubmed-meshheading:15919446-RNA, Messenger,
pubmed-meshheading:15919446-Tacrolimus
|
pubmed:year |
2005
|
pubmed:articleTitle |
Initial dosage adjustment for oral administration of tacrolimus using the intestinal MDR1 level in living-donor liver transplant recipients.
|
pubmed:affiliation |
Department of Pharmacy, Kyoto University Hospital, Kyoto University, Kyoto, Japan.
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|